JP7796719B2 - 抗タウ抗体 - Google Patents

抗タウ抗体

Info

Publication number
JP7796719B2
JP7796719B2 JP2023501609A JP2023501609A JP7796719B2 JP 7796719 B2 JP7796719 B2 JP 7796719B2 JP 2023501609 A JP2023501609 A JP 2023501609A JP 2023501609 A JP2023501609 A JP 2023501609A JP 7796719 B2 JP7796719 B2 JP 7796719B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
sequence set
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533768A5 (enExample
JP2023533768A (ja
Inventor
チャールズ ロバート ハリントン
ソーマン ソーミャ パリル
アンドリュー ジャスティン ラドクリフ ポーター
クロード ミシェル ウィシック
ムハンマド アラスト
ルイス カーク ペニー
リチャード ロフトハウス
Original Assignee
ジーティーインヴェント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーティーインヴェント リミテッド filed Critical ジーティーインヴェント リミテッド
Publication of JP2023533768A publication Critical patent/JP2023533768A/ja
Publication of JP2023533768A5 publication Critical patent/JP2023533768A5/ja
Application granted granted Critical
Publication of JP7796719B2 publication Critical patent/JP7796719B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023501609A 2020-07-10 2021-07-09 抗タウ抗体 Active JP7796719B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010652.2 2020-07-10
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (3)

Publication Number Publication Date
JP2023533768A JP2023533768A (ja) 2023-08-04
JP2023533768A5 JP2023533768A5 (enExample) 2024-05-09
JP7796719B2 true JP7796719B2 (ja) 2026-01-09

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501609A Active JP7796719B2 (ja) 2020-07-10 2021-07-09 抗タウ抗体

Country Status (10)

Country Link
US (1) US12624096B2 (enExample)
EP (1) EP4178980A1 (enExample)
JP (1) JP7796719B2 (enExample)
KR (1) KR20230038721A (enExample)
CN (1) CN116194479B (enExample)
AU (1) AU2021306653A1 (enExample)
CA (1) CA3185175A1 (enExample)
GB (1) GB202010652D0 (enExample)
TW (1) TWI912331B (enExample)
WO (1) WO2022008719A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504570A (ja) 2013-11-27 2017-02-09 アイピエリアン，インコーポレイティド タウオパチーの処置方法
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
KR101231777B1 (ko) 2010-11-25 2013-02-08 부산대학교 산학협력단 ＧＳＫ３β 저해를 통한 타우 과인산화 저해제 탐색 방법
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504570A (ja) 2013-11-27 2017-02-09 アイピエリアン，インコーポレイティド タウオパチーの処置方法
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法

Also Published As

Publication number Publication date
US20230257452A1 (en) 2023-08-17
EP4178980A1 (en) 2023-05-17
CN116194479B (zh) 2026-05-22
CN116194479A (zh) 2023-05-30
KR20230038721A (ko) 2023-03-21
WO2022008719A1 (en) 2022-01-13
US12624096B2 (en) 2026-05-12
TWI912331B (zh) 2026-01-21
TW202214686A (zh) 2022-04-16
CA3185175A1 (en) 2022-01-13
GB202010652D0 (en) 2020-08-26
JP2023533768A (ja) 2023-08-04
AU2021306653A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
US7763249B2 (en) Human anti-amyloid β peptide antibody and fragment of said antibody
JP7722990B2 (ja) アミロイド沈着物を標的化するための修飾免疫グロブリン
BR112020018868A2 (pt) métodos baseados em anticorpo para detectar e tratar doença de alzheimer
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CA2787566A1 (en) Anticoagulant antidotes
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US12624096B2 (en) Anti-tau antibodies and methods of use thereof
US20210139568A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
GB2585252A (en) Tau epitope and binding molecules
JP2023531822A (ja) タウ結合分子
RU2855123C1 (ru) Антитела против тау
US20250355001A1 (en) Method for detecting a tau protein fragment in a sample

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150